. Author manuscript; available in PMC: 2011 Dec 12.

Published in final edited form as: HIV Ther. 2010 Nov;4(6):693–711. doi: 10.2217/hiv.10.47

Table 3.

Changes in measures of cardiovascular function in subjects switching antiretroviral therapy

Investigators/study (year)	Switch	Measurement	Result	Refs.
Flammer et al.^†(2009)	Other PI to unboosted atazanavir	FMD	NC	[23]
SABAR (2010)	Other PI to atazanavir/ritonavir	Cardiovascular inflammatory markers	NC	[21]
SIROCCO (2007)	Efavirenz to Nevirapine	FRS	−2% 10-year CVD risk	[38]
STEAL (2009)	Other NRTIs to abacavir/3TC or tenofovir/emtricitabine	Cardiovascular event rate	Tenofovir vs abacavir 0.3 vs 2.2 events/ 100 person-years; p = 0.048	[35]

^†

Within-arm p-value reported (otherwise, between-arm p-value reported).

3TC: Lamivudine; CVD: Cardiovascular disease; FMD: Flow-mediated dilatation; FRS: Framingham risk score; NC: No (significant) change; NRTI: Nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor.